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Background: Sunitinib is widely used as ﬁ  rst-line treatment for metastatic clear cell renal 
cancer (MCRC). No reports are known of treatment after sunitinib failure. As irinotecan, 
cisplatin, and mitomycin-C (IPM) chemotherapy has been reported to inﬂ  uence MCRC after 
progression on cytokine therapy, we report on the outcome of 11 patients treated with IPM 
after sunitinib failure.
Patients and methods: Eleven patients with progression of disease on sunitinib therapy were 
treated with 4, monthly cycles of monthly IPM.
Results: Nine out of 11 patients progressed during IPM therapy. The median time to progres-
sion was 1.4 months (95% CI: 0.7–2.1 months), while the overall survival was 4.2 months 
(95% CI: 0.9–2.3). Overall 10 patients have died of progressive renal cancer. One patient had 
a radiological response to therapy and remains progression free 11 months after treatment. Four 
of the 10 patients required a dose reduction for grade 3 or 4 toxicities.
Conclusions: IPM alone does not appear to beneﬁ  t patients with MCRC who previously 
progressed during sunitinib therapy. The median progression-free survival and overall survival 
for these patients is short.
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Introduction
Multitargeted tyrosine kinase inhibitors (TKIs) have revolutionised the treatment 
of metastatic clear cell renal cancer (Motzer et al 2006; Escuider et al 2007). Sunitinib 
has superseded cytokine therapy as ﬁ  rst line treatment for this disease (Motzer et al 
2007).
Patient results after treatment with cytokine therapy have been reported (Ryan 
et al 2002; Shamash et al 2003; Stadler et al 2003; Motzer et al 2004; Porta et al 
2004), but currently there are no data on treatment and outcome after progression on 
sunitinib therapy.
Single agent chemotherapy has little effect in metastatic clear cell renal cancer 
(Kish et al 1994; De Mulder et al 1996). However, the role of combination chemo-
therapy in cytokine refractory disease was already under investigatation before the 
introduction of TKIs (Ryan et al 2002; Stadler et al 2003; Porta et al 2004; Patard et al 
2008). Our group published a phase II study using irinotecan cisplatin and mitomycin 
(IPM) in cytokine refractory disease (Shamash et al 2003). Results were comparable 
to historical controls treated with chemotherapy, with a progression-free survival of 
4.8 months and overall survival (OS) of 9.2 months.
We have continued to use IPM in patients with refractory renal cell cancer and in 
this short report we describe our experience (as part of a prospective observational 
study) using this regimen after progression on sunitinib therapy.OncoTargets and Therapy 2008:1 36
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Methods
Since the publication of the IPM regimen (Shamash et al 
2003) the policy of our unit has been to offer this treatment 
to patients with sunitinib refractory metastatic renal cancer. 
Patients with histologically conﬁ  rmed metastatic clear cell 
renal cancer, who were progressing on (RECIST criteria) 
(n = 10) or intolerant to sunitinib (n = 1), were included, after 
giving informed consent according to standard guidelines. CT 
scanning of the chest, abdomen, and pelvis was performed 
every 2 complete cycles of treatment.
The IPM regimen
Treatment was administered on an outpatient basis as follows: 
intravenous (iv) irinotecan 70 mg/m2, cisplatin 40 mg/m2, 
mitomycin-C 6 mg/m2 was administered on day 1, and 
irinotecan 70 mg/m2, cisplatin 40 mg/m2 was administered 
on day 15 of a 28-day cycle. Anti-emetic granisetron 1 mg 
iv and dexamethasone 8 mg iv were co-administered rou-
tinely with each cycle. Blood cell counts and chemistry 
panels were repeated with every treatment. Treatment was 
delayed by one week in the event of bone marrow suppres-
sion (total leukocyte count 3 × 109 cells/L, neutrophil 
count 1.5 × 109 cells/L, or platelet count 100 × 109 cells/L). 
This regimen has been standard second line therapy for meta-
static renal tumors at our unit since the publication of our 
work in 2003 (Shamash et al 2003).
Statistics
Survival was calculated according to the method of Kaplan 
and Meier.
Results (Table 1)
The median age of the 11 patients with clear cell renal 
tumors was 53.5 (range: 42–69). The median OS from time 
of diagnosis of metastatic renal cancer was 20.5 months 
(range: 6.1–19.7).
Treatment prior to IPM chemotherapy
Cytokine therapy
The Memorial Sloan Kettering risk factors for these patients 
at initial diagnosis were: poor risk disease (n = 1), inter-
mediate risk disease (n = 8), and favourable risk disease 
(n = 2). All but 1 patient had had a nephrectomy and all had 
received immune therapy as ﬁ  rst line therapy followed by 
sunitinib therapy as second line therapy. None of the patients 
responded to immune therapy (interferon-alpha n = 9, inter-
feron, 5FU, and il-2 n = 2) and the median time to progression 
on cytokine therapy was 4 months (range: 2–17 months).
T
a
b
l
e
 
1
 
P
a
t
i
e
n
t
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
a
n
d
 
o
u
t
c
o
m
e
R
i
s
k
 
a
t
 
t
i
m
e
 
o
f
 
s
u
n
i
t
i
n
i
b
 
t
h
e
r
a
p
y
 
(
M
o
t
z
e
r
 
e
t
 
a
l
 
2
0
0
4
)
I
n
i
t
i
a
l
 
r
e
s
p
o
n
s
e
 
t
o
 
s
u
n
i
t
i
n
i
b
 
t
h
e
r
a
p
y
T
T
P
 
d
u
r
i
n
g
 
s
u
n
i
t
i
n
i
b
 
t
h
e
r
a
p
y
R
i
s
k
 
a
t
 
t
i
m
e
 
o
f
 
I
P
M
 
(
M
o
t
z
e
r
 
e
t
 
a
l
 
2
0
0
4
)
R
e
s
p
o
n
s
e
 
t
o
 
I
P
M
 
a
f
t
e
r
 
2
 
c
y
c
l
e
s
G
r
a
d
e
 
3
 
o
r
 
4
 
t
o
x
i
c
i
t
y
 
o
n
 
I
P
M
T
T
P
 
o
n
 
I
P
M
 
(
m
o
n
t
h
s
)
O
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
 
f
r
o
m
 
t
i
m
e
 
o
f
 
s
t
a
r
t
i
n
g
 
I
P
M
 
(
m
o
n
t
h
s
)
O
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
 
f
r
o
m
 
t
i
m
e
 
o
f
 
d
i
a
g
n
o
s
i
s
 
o
f
 
m
e
t
a
s
t
a
t
i
c
 
r
e
n
a
l
 
c
a
n
c
e
r
i
n
t
P
R
1
4
.
3
i
n
t
P
D
–
1
,
4
4
.
2
3
1
P
o
o
r
P
D
2
.
8
p
o
o
r
P
D
–
0
.
5
0
.
5
6
.
1
I
n
t
P
D
4
.
8
p
o
o
r
P
D
D
i
a
0
.
9
2
.
1
9
.
2
I
n
t
S
D
8
.
3
p
o
o
r
P
D
–
1
.
8
3
.
0
2
7
.
4
G
o
o
d
P
R
1
2
.
2
p
o
o
r
P
D
D
i
a
,
 
l
e
t
h
e
r
g
y
1
.
4
1
.
6
3
3
.
0
P
o
o
r
S
D
7
.
2
i
n
t
P
D
L
e
t
h
a
r
g
y
2
.
8
6
.
2
1
6
.
9
i
n
t
P
R
6
.
2
p
o
o
r
P
R
–
1
1
.
0
P
F
1
1
.
0
A
3
4
.
3
A
P
o
o
r
S
D
2
.
1
p
o
o
r
S
D
N
e
u
t
.
 
S
e
p
s
i
s
.
 
L
e
t
h
a
r
g
y
2
.
3
 
T
7
.
8
1
8
.
1
i
n
t
S
D
1
0
.
5
p
o
o
r
P
D
–
0
.
9
5
2
0
.
5
p
o
o
r
S
D
2
.
7
p
o
o
r
P
D
–
1
.
8
5
.
3
2
4
.
4
I
n
t
P
R
1
1
.
3
i
n
t
P
D
–
1
.
4
2
.
1
1
5
.
6
N
o
t
e
s
:
 
A
A
l
i
v
e
,
 
P
F
P
r
o
g
r
e
s
s
i
o
n
 
f
r
e
e
,
 
T
S
t
o
p
p
e
d
 
d
u
e
 
t
o
 
t
o
x
i
c
i
t
y
.
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
T
T
P
,
 
t
i
m
e
 
t
o
 
p
r
o
g
r
e
s
s
i
o
n
;
 
I
n
t
,
 
i
n
t
e
r
m
e
d
i
a
t
e
;
 
N
e
u
t
,
 
n
e
u
t
r
o
p
e
n
i
c
;
 
D
i
a
,
 
d
i
a
r
r
h
e
a
.OncoTargets and Therapy 2008:1 37
Sunitinib in renal cancer
Sunitinib therapy
All 11 patients went on to receive sunitinib therapy. Two 
patients had progression of disease, 5 had stable disease, 
and 4 had a partial response to treatment after 2 cycles of 
therapy. The median number of cycles administered was 
4 and the median time on therapy was 7.2 months (range: 
2.1–11.3 weeks). The prognostic factors for these pre-treated 
patients are shown in Table 1.
Response to IPM chemotherapy 
post sunitinib therapy
Only 2 patients received all 4 cycles of IPM chemotherapy 
as planned. All but 2 patients progressed either clinically 
or radiologically by the end of the second cycle of chemo-
therapy. One patient had stable disease but did not complete 
treatment (due to grade 3 toxicity), while the other had a 
partial response to treatment. This patient is alive and contin-
ues in remission 11 months after chemotherapy. The median 
time to progression from time of starting chemotherapy was 
1.4 months (95% CI: 0.9–2.3 months), while the OS was 
4.2 months (95% CI:1.6–6.2 months). Ten patients have died 
of progressive renal cancer (Figures 1 and 2).
Toxicity associated 
with IPM chemotherapy
Four of the 11 patients required a dose reduction for grade 
3 or grade 4 toxicity, which included diarrhea (n = 2) and 
neutropenic sepsis (n = 1) and lethargy (n = 2). One of these 
patients stopped the IPM after 3 cycles because of toxicity.
Discussion
Sunitinib is now widely used as ﬁ  rst line therapy in meta-
static clear cell renal cancer. There are no published data on 
the management of patients with progression of disease on 
sunitinib therapy. Importantly, it is not clear whether patients 
should stop sunitinib therapy at progression (Motzer et al 
2006, 2007). The use of sequential TKIs, such as a switch 
from sunitinib to sorafenib or axitinib on progression is 
common, but not yet of proven beneﬁ  t (Patard et al 2008). 
These sequential regimens are undergoing intense prospec-
tive evaluation and the results are eagerly awaited.
It is widely accepted that renal cancer is largely resistent to 
chemotherapy in the majority of patients. The data presented 
here describes 11 patients who switched to IPM chemotherapy 
at progression (n = 10) or intolerance (n = 1) after sunitinib. 
The median time to progression (TTP) and median OS 
were 1.4 and 4.2 months, respectively. These results appear 
shorter when compared with IPM after cytokine therapy 
(TTP 4.8 months and OS 9.2 months) (Shamash et al 2003). 
Although the numbers are small, the data suggest that IPM 
chemotherapy in this setting does not appear to be of beneﬁ  t. 
One patient did respond to therapy, but the signiﬁ  cance of this 
is not clear (Dreicer 2006). Moreover this regimen was not 
particularly well tolerated in this setting with more than a third 
of the patients developing grade 3 or 4 toxicity. This ﬁ  nding, 
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Figure 1 Kaplan Meier curve showing overall survival associated with IPM chemotherapy after progression on sunitinib therapy.OncoTargets and Therapy 2008:1 38
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in conjunction with the poor response data, prompted us to 
halt further use of this regimen in this setting.
A number of prognostic factors have been identiﬁ  ed for 
patients who have progressed on cytokine therapy (Motzer 
et al 2004). Eight of the 11 patients presented here were in 
this poor prognosis group. The median survival for these 
patients is predicted to be only 5.4 months, which may help 
explain, in part, why the results are poor. Indeed future 
investigation in this area should perhaps focus on patients 
with better prognostic factors.
There are 3 other possible explanations for these poor 
results. Firstly IPM was used as third line rather than second 
line therapy (after cytokine failure and sunitinib failure). 
Secondly, patients who progress on sunitinib may have more 
advanced and aggressive disease at the time of progression, 
compared with those who fail on cytokine therapy. This issue 
is unresolved in previously published studies (Motzer et al 
2006), although such results might be expected to indicate 
higher response rates with chemotherapy than those seen in 
this work. Finally, it is possible that stopping sunitinib is asso-
ciated with acceleration of disease, as seen with imatinib in 
gastro-intestinal stromal tumors (GIST) (Blay et al 2007).
The results of the IPM regimen, in the cytokine refractory 
setting, are comparable to other combination regimes used 
in this setting (gemicitabine and 5FU: TTP 6.6 months, OS 
11 months (Rini et al 2000); gemicitabine and oxaliplatin 
TTP 2.5 months, mean OS 9.5 months (Porta et al 2004). 
The addition of cisplatin to gemicitabine and 5FU did not 
enhance these results any further (George et al 2002). Therefore 
one would not necessarily expect the results with these other 
chemotherapy regimes to be dramatically different, although the 
in vitro data on this topic is limited. Nevertheless the response 
and survival data presented here is poor and, in our opinion, 
does not warrant further investigation in this setting.
In view of the poor survival rates of these patients, this 
may not be the ideal setting to investigate new treatment in 
isolation in renal cancer. Other studies may wish to recruit 
patients with better prognostic factors or add treatments to 
sunitinib rather than stop it. It does not appear that IPM che-
motherapy beneﬁ  ts patients with metastatic clear cell renal 
cancer who previously received sunitinib therapy.
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